SCHEMIA Australia Update

National Heart, Lung, and Blood Institute

September 2016

INTERNATIONAL STUDY OF COMPARATIVE HEALTH EFFECTIVENESS WITH MEDICAL AND INVASIVE APPROACHES

NYU Cardiovascular Clinical Research Center

ISCHEMIA Trial Update (As of September 9, 2016)

Enrolled Worldwide: 5734 Australia: 33

Randomized Worldwide: 3392 Australia: 26

ISCHEMIA-CKD Update

Enrolled Worldwide: 358 Australia: I

Randomized Worldwide: 341 Australia: I

CIAO-ISCHEMIA Update

Enrolled Worldwide: 107 Australia: 0

Country Leader Prof. Joseph Selvanayagam

SAHMRI Deirdre Murphy, CRA

ISCHEMIA-CKD

Lead Nephrologist Dr. Magid Fahim

ISCHEMIA

Clinical Coordinating Center

www.ischemiatrial.org www.ischemiackd.org

Email: ischemia@nyumc.org Phone: +1-212-263-4225 Fax: +1-646-754-9621

Regional Team Alexandra Brackenheimer Kevin Chan Michelle Yee

Clinical Help Line (Toll-free) Australia: 1800027430

Welcome Warmth by...

Breaking Recruitment Barriers!

Are patients going straight to the cath lab?

- Establish frequent communication with stress lab readers
- Screen stress labs everyday to identify potential eligible patients before they are referred for cardiac catheterization



Do physicians frequently refuse patient participation in the study?

- PI should meet with physicians to understand circumstances—review evidence to support revascularization in SIHD with colleagues and encourage a trial of medical therapy before referral to trial or to cath lab
- Build equipoise through meetings and discussions speakers, slides, and relevant publications are available from the CCC



Is there a low volume of cases with sufficient ischemia?

- Screen additional stress labs—stress tests performed in external imaging labs are acceptable and can be reviewed by study team
- Expand referral sources by engaging private practices affiliated with referring centers

Do patients with at least moderate ischemia meet other exclusion criteria?

- Keep a list of patient who may become eligible in the future—e.g. after an elective surgery is performed, 2 months to elapse after ACS, 12 months to elapse after PCI or CABG, etc.
- Contact the CCC when uncertain about eligibility

The enrollment period is expected to end in December 2017.

REMINDER

With the end of the trial in sight, we need your help to reach our randomization target! Stay tuned for a webinar in October to discuss recruitment strategies for the Asia/Pacific region.

Study Teams in Australia		
Site Name	Enrolled	Randomized
Royal Perth Hospital , Western Australia Dr. Graham Hillis, Michelle Bonner, Kim Ireland	2	2
John Hunter Hospital, New South Wales Dr. Suku Thambar, Claire-Marie Cummins	8	5
Flinders Medical Centre, South Australia Dr. Majo Joseph, Dr. Joseph Selvanayagam, Sau Lee	18 (+1 CKD)	16 (+1 CKD)
Queen Elizabeth Hospital, South Australia Dr. John Beltrame, Marilyn Black, Jeanette Stansborough	5	3
Princess Alexandra Hospital, Queensland Dr. Magid Fahim, Amanda Coburn, Joanna Sudak	0	0